Navigation Links
Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences
Date:2/24/2009

Produces 98% pure protein

THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it's contract research and development organization, Aragen Bioscience, has completed development of a recombinant cell line and initial production process for UCB-1 (NELL-1) recombinant protein.

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the founding scientists at UCLA. The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX(R) demineralized bone matrix to promote bone growth in spinal fusion.

Aragen has produced UCB-1 (NELL-1) at a purity level Bone Biologics believes is sufficient for IDE submission. Results in animal trials using that protein have exhibited rapid bone growth, high quality of bone, and no ectopic bone growth. Efforts will now focus on scaling that process up to produce clinical grade product.

The platform technology will be subject to the FDA review and approval process, including clinical trials. It is not currently approved for use in humans.

Rick Srigley, CEO of Aragen Bioscience said, "This project has been exciting for us. UCB-1 (NELL-1) is a complex and challenging protein, but we believe that the cell line and process we have developed for Bone Biologics can be scaled up to provide protein at purity and productivity levels sufficient for Phase I clinical studies." William Jay Treat, Ph.D., President of Southwest BioProcessing Associates LLC, who has extensive experience in cell line development, scale-up optimization and commercial manufacturing provided key guidance during this process to Bone Biologics, said, "The professionalism, expertise, and awareness of keeping to a timeline by Aragen has developed a manufacturing process that is suitable to move to the next phase of UCB-1 (NELL-1) manufacturing.

About Aragen Biosciences

Aragen Biosciences, Inc. is a contract research and development organization in Morgan Hill, California. Aragen specializes in recombinant cell line and hybridoma development, cell culture and purification process development and production, cell-based assays and custom immunological services. (http://www.aragenbio.com/)

About Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space. The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years. This platform technology is the unique UCB-1 (NELL-1) protein formulated with tissue-specific scaffolds to only deliver the intended outcomes. The lead product effort is to promote bone growth in spinal fusion.


'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
2. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
5. Savient Submits Biologics License Application (BLA) for pegloticase
6. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
7. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
8. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
9. NuVasive Completes Acquisition of Osteocel Biologics Business
10. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
11. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... ... Asymmetrex will deliver a talk on its first-in-class technologies for tissue ... 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and data management ... The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” , “From ... end users facing some of the most complex data challenges in the industry,” said ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... Touch screen mobile devices with fingerprint recognition for secure access, voice recognition for ... a few ways consumers are interacting with biometrics technology today. But if ...
(Date:4/27/2016)... ... 27, 2016 , ... The Board of Directors of Biohaven ... Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. ... responsible for the commercialization of multiple orphan drug indications. Mr. Tilton has ...
Breaking Biology Technology:
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):